Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant HAIC combined with tislelizumab after resection for high-risk hepatocellular carcinoma
ChiCTR2600131795Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Disease-free survival and Safety and tolerability. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumabdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600131795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131795.